Pennsylvania woman was taken off of the Ozempic injections after her stomach pains and constant vomiting symptoms were linked to gastroparesis, also known as stomach paralysis.
Many of the incidents involved overdoses with compounded versions of Ozempic and Wegovy's active ingredient, semaglutide.
Plaintiff says Novo Nordisk downplayed the potential stomach paralysis side effects from Ozempic, by failing to accurately describe the extent of the risk on the medication's label and prescribing information.
Novo Nordisk has downplayed the severity of gastrointestinal problems caused by Ozempic, according to lawsuit filed by a user left with gastroparesis, also known as a paralyzed stomach.
Amid rising concerns about the widespread use of Ozempic, European investigators are expanding an investigation into potential suicide side effects associated with new diabetes and weight loss drugs.
Attorneys are investigating more than 10,000 potential Ozempic, Wegovy and Mounjaro lawsuits that may soon be filed on behalf of users who experienced stomach paralysis injuries.
The findings are likely to further increase the use of Wegovy, Ozempic and similar drugs, despite growing concerns about severe stomach problems experienced by some users.
In response to a failure to warn lawsuit brought by a Louisiana woman who developed painful stomach paralysis, the manufacturer claims Ozempic gastrointestinal side effects were well disclosed to doctors and consumers
Plaintiff was hospitalized due to Ozempic gastroparesis, which led to a gastrointestinal blockage, chronic diarrhea, heartburn, pain and hospitalization.
Amid widespread use of Ozempic, Wegovy and similar new weight loss drugs, there have been concerns that side effects may increase the risk of thryoid cancer. However, European regulators found no evidence.
